Form 4: NEA 17 Boosts Stake in Korro Bio with New Securities

New Enterprise Associates 17, L.P. increased its beneficial ownership in Korro Bio, Inc. through the acquisition of common stock and pre-funded warrants.

Summary

• New Enterprise Associates 17, L.P. (NEA 17), a 10% owner and director of Korro Bio, Inc. (KRRO), acquired additional securities.
• On March 10, 2026, NEA 17 acquired 207,100 shares of common stock at a price of $11.11 per share.
• Following this transaction, NEA 17 beneficially owns 1,297,893 shares of common stock.
• NEA 17 also acquired 242,945 pre-funded warrants on March 10, 2026, at a price of $11.109 per warrant, with an exercise price of $0.001.
• These warrants are exercisable at any time, subject to a beneficial ownership limitation of 9.99%, which can be increased to 19.99% with 61 days' prior notice.
• The securities were acquired directly from Korro Bio, Inc. pursuant to a Subscription Agreement dated March 9, 2026.
• NEA Partners 17, L.P., NEA 17 GP, LLC, and their individual managers (Forest Baskett, Ali Behbahani, Carmen Chang, Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott Sandell, Paul Walker, and Rick Yang) are indirect reporting persons, disclaiming beneficial ownership for portions without pecuniary interest.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor and director is increasing its stake, suggesting continued confidence and potentially providing capital to the company.

Positives

• A significant institutional investor and director, New Enterprise Associates 17, L.P., increased its stake in Korro Bio, Inc., indicating confidence in the company's future prospects.
• The acquisition of shares and pre-funded warrants directly from the issuer suggests a capital infusion for Korro Bio, Inc.

Risks

• The pre-funded warrants have an exercise limitation, preventing the holder from exceeding 9.99% beneficial ownership (adjustable to 19.99%), which could impact the investor's ability to fully convert their holdings if not managed carefully.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing beyond the nature of the warrants.

Management Comments

• The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Indirect Reporting Persons have no pecuniary interest.

Industry Context

StockSavvy.ai notes that insider buying, especially from significant institutional investors like New Enterprise Associates, can often be interpreted as a positive signal in the biotechnology sector, suggesting confidence in the company's pipeline or strategic direction. Such investments are common for venture capital firms that also hold board seats in their portfolio companies.

Comparison to Industry Standards

• The acquisition of additional equity by a major institutional investor and board member is a common occurrence in the biotech industry, particularly for companies like Korro Bio, Inc. (KRRO) that are often in development stages and require ongoing capital.
• The pricing of the common stock and pre-funded warrants at approximately $11.11 suggests a recent valuation point, which can be compared to recent financing rounds or market prices of similar-stage biotech companies.
• The structure involving pre-funded warrants with a low exercise price and ownership limitations is a standard mechanism used in private placements to manage immediate dilution and regulatory ownership thresholds.

Related Party Transactions

• The acquisition of securities by New Enterprise Associates 17, L.P., a 10% owner and director, from Korro Bio, Inc. constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The capital infusion from a significant investor could be viewed positively, potentially strengthening the company's financial position. Existing shareholders might experience some dilution from the issuance of new shares and warrants, though the specific impact depends on the total shares outstanding.
• Company: Receives capital from the issuance of common stock and pre-funded warrants, supporting operations and strategic initiatives.

Next Steps

• The pre-funded warrants are exercisable at any time, subject to beneficial ownership limitations.

Key Dates

Recommendation

The acquisition of additional shares and warrants by a significant institutional investor and director, New Enterprise Associates 17, L.P., signals confidence in Korro Bio, Inc. and provides a capital infusion. However, this Form 4 filing does not provide comprehensive financial results or strategic updates to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future company performance and broader market conditions.

Keywords

Korro Bio, KRRO, New Enterprise Associates, NEA 17, Insider Buying, Form 4, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Biotechnology, Investment